Inhaled insulin – a new therapeutic option in the treatment of diabetes mellitus

2003 ◽  
Vol 4 (2) ◽  
pp. 191-200 ◽  
Author(s):  
Juan José Díez ◽  
Pedro Iglesias
Keyword(s):  
Diabetes Mellitus ◽  
Therapeutic Option ◽  
Inhaled Insulin ◽  
Treatment Of Diabetes

Pancreatic stem cells – new therapeutic option for the treatment of diabetes mellitus type 1

2002 ◽  
Vol 59 (11) ◽  
pp. 599-602
Author(s):  
Zulewski
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Ex Vivo ◽  
Therapeutic Option ◽  
Diabetes Mellitus Type 1 ◽  
Diabetes Mellitus Typ 1 ◽  
Pancreatic Stem Cells ◽  
Treatment Of Diabetes

Die Entdeckung von multipotentiellen Stammzellen in embryonalen und adulten Langerhans’schen Inseln des Pankreas lässt Hoffnungen keimen auf eine künftige Stammzell basierte Therapie des Diabetes mellitus Typ 1. Diese Stammzellen sind charakterisiert durch die Expression des Neurofilamentes Nestin, einem Marker für Stammzellen des Zentralen Nervensystems. Nestin positive Zellen aus humanen pankreatischen Inseln können ex vivo isoliert und expandiert werden. Sie bergen das Potenzial sich in vitro sowohl in Zellen mit pankreatisch-endokrinem als auch exokrinem Phänotyp zu differenzieren mit der Expression von Insulin und Glukagon sowie exokrinen Markern wie dem Zytokeratin19 und der Amylase. Zusätzlich haben diese pankreatischen Stammzellen die Fähigkeit in Kultur Proteine zu exprimieren, die einem hepatischen Phänotyp entsprechen. Die Differenzierung Nestin-positiver Stammzellen in Insulin exprimierende Zellen wird entscheidend gefördert durch das insulinotrope Hormon GLP-1.

scholarly journals Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus

2015 ◽  
Vol 2015 ◽  
pp. 1-19 ◽  
Author(s):  
Seyed Jafar Hashemian ◽  
Marjan Kouhnavard ◽  
Ensieh Nasli-Esfahani
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Therapeutic Option ◽  
Autoimmune Disorder ◽  
Cell Types ◽  
Therapeutic Modality ◽  
Diabetic Patients ◽  
Cell Therapies ◽  
Treatment Of Diabetes

Type 1 diabetes mellitus (T1DM) is an autoimmune disorder that leads to beta cell destruction and lowered insulin production. In recent years, stem cell therapies have opened up new horizons to treatment of diabetes mellitus. Among all kinds of stem cells, mesenchymal stem cells (MSCs) have been shown to be an interesting therapeutic option based on their immunomodulatory properties and differentiation potentials confirmed in various experimental and clinical trial studies. In this review, we discuss MSCs differential potentials in differentiation into insulin-producing cells (IPCs) from various sources and also have an overview on currently understood mechanisms through which MSCs exhibit their immunomodulatory effects. Other important issues that are provided in this review, due to their importance in the field of cell therapy, are genetic manipulations (as a new biotechnological method), routes of transplantation, combination of MSCs with other cell types, frequency of transplantation, and special considerations regarding diabetic patients’ autologous MSCs transplantation. At the end, utilization of biomaterials either as encapsulation tools or as scaffolds to prevent immune rejection, preparation of tridimensional vascularized microenvironment, and completed or ongoing clinical trials using MSCs are discussed. Despite all unresolved concerns about clinical applications of MSCs, this group of stem cells still remains a promising therapeutic modality for treatment of diabetes.

Treatment of diabetes mellitus: Implications of the use of oral agents

1999 ◽  
Vol 138 (4) ◽  
pp. s334-s337 ◽  
Author(s):  
S RAO ◽  
A BETHEL ◽  
M FEINGLOS
Keyword(s):  
Diabetes Mellitus ◽  
Oral Agents ◽  
Treatment Of Diabetes

Insulin Initiation and Concomitant OHA (Oral Hypoglycaemic Agents) in Treatment of Diabetes Mellitus—Results of the Indian Human Insulin Registry (INHIRIT)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2293-PUB ◽  
Author(s):  
VEERANNA KARADI ◽  
DILIP PAWAR ◽  
SARAH JABEEN ◽  
SANDEEP S. ◽  
SAPTARSHI BOSE ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Human Insulin ◽  
Insulin Initiation ◽  
Oral Hypoglycaemic Agents ◽  
Hypoglycaemic Agents ◽  
Treatment Of Diabetes

Association and treatment of diabetes in patients affected by Covid-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1198-1201
Author(s):  
Syed Yasir Afaque
Keyword(s):  
Diabetes Mellitus ◽  
Prognostic Value ◽  
Heart Diseases ◽  
The Novel ◽  
The World ◽  
Treatment Of Diabetes ◽  
Coronavirus Infection ◽  
Composite Outcomes ◽  
Novel Coronavirus ◽  
The Impact

In December 2019, a unique coronavirus infection, SARS-CoV-2, was first identified in the province of Wuhan in China. Since then, it spread rapidly all over the world and has been responsible for a large number of morbidity and mortality among humans. According to a latest study, Diabetes mellitus, heart diseases, Hypertension etc. are being considered important risk factors for the development of this infection and is also associated with unfavorable outcomes in these patients. There is little evidence concerning the trail back of these patients possibly because of a small number of participants and people who experienced primary composite outcomes (such as admission in the ICU, usage of machine-driven ventilation or even fatality of these patients). Until now, there are no academic findings that have proven independent prognostic value of diabetes on death in the novel Coronavirus patients. However, there are several conjectures linking Diabetes with the impact as well as progression of COVID-19 in these patients. The aim of this review is to acknowledge about the association amongst Diabetes and the novel Coronavirus and the result of the infection in such patients.

Metabolic surgery, a new paradigm for the treatment of diabetes

2019 ◽  
Vol 30 (4) ◽  
pp. 477-485
Author(s):  
R Balongo García ◽  
D Bejarano Gómez-Serna ◽  
A de la Rosa Báez ◽  
D Molina García ◽  
B García del Pino ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Surgery ◽  
New Paradigm ◽  
Calidad De Vida ◽  
Treatment Of Diabetes ◽  
Sistemas Sanitarios

Resumen La diabetes mellitus tipo II (DM2) es una enfermedad crónica, progresiva e incurable, que ocasiona una reducción de la esperanza y de la calidad de vida. Se está produciendo un incremento epidémico global de la misma asociada a la obesidad, y a largo plazo se convertirá en la mayor carga sobre los sistemas sanitarios. Aunque existe un tratamiento efectivo para la diabetes, muchos de los pacientes sólo con el tratamiento médico no consiguen los objetivos terapéuticos mínimos para el control del riesgo microvascular. Las técnicas quirúrgicas para la obesidad mórbida han demostrado que pueden controlar la hiperglucemia, y existe consenso para su uso como forma de tratamiento para algunos pacientes desde 2015. Dado que los objetivos, el tipo de respuesta y los criterios de efectividad no están relacionados directamente con el sobrepeso, estamos ante un nuevo paradigma, definido por el término cirugía metabólica.

Berberine in the treatment of diabetes mellitus: a review

2020 ◽  
Vol 20 ◽  
Author(s):  
Aleksandra Baska ◽  
Kamil Leis ◽  
Przemysław Gałązka
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Intestinal Flora ◽  
Glucose Absorption ◽  
Hepatocyte Nuclear Factor ◽  
Peripheral Tissues ◽  
Macrophages Polarization ◽  
Treatment Of Diabetes ◽  
Hepatocyte Nuclear Factor 4

: Berberine is an alkaloid found in plants. It has e.g. neuroprotective, anti-inflammatory and hypolipidemic activity. The research proves that it also strongly impacts the carbohydrate metabolism. The compound also protects pancreatic βcells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.

Sign in / Sign up

Export Citation Format

Share Document